134 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
29 Feb 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm
2b X-TOLE clinical trial. These multicenter, randomized, double-blind, placebo-controlled trials are evaluating the clinical efficacy, safety … the clinical efficacy, safety, and tolerability of 25 mg of XEN1101 administered with food as adjunctive treatment in approximately 160 patients with PGTCS
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
, double-blind, placebo-controlled trials are evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of XEN1101 administered … -clonic seizures, or PGTCS. This multicenter, randomized, double-blind, placebo-controlled study is evaluating the clinical efficacy, safety
8-K
EX-1.1
43j3na
30 Nov 23
Entry into a Material Definitive Agreement
4:15pm
424B5
mc5fx25ic f0
29 Nov 23
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
x2ziy
27 Nov 23
Other Events
7:03am
8-K
4zoqfplhcsbv3i
27 Nov 23
Other Events
7:03am
8-K
EX-99.1
no57z3e90vouv jmcwas
9 Nov 23
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
4:06pm
8-K
EX-99.1
h7lxny7 rhjh6sog6
8 Nov 23
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
7hlpqfvyrxhgw
9 Aug 23
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
kbqxpq4g5em0rvv p1
8 Aug 23
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
4:07pm
8-K
EX-99.1
mf0xvsgg
9 May 23
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm